Halozyme Therapeutics Stock Price. Everything You Need To Know About The Halozyme Therapeutics Stock!
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 393 full-time employees. The company went IPO on 2003-01-30. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators’ compounds. The Company’s proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. The Company’s commercially approved product, Hylenex recombinant (Hylenex), and its ENHANZE partners approved products and product candidates are based on rHuPH20. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that is designed to provide commercial or functional advantages. The company has a commercial portfolio of proprietary products, including XYOSTED, TLANDO and NOCDURNA and partnered commercial products and ongoing product development programs with several pharmaceutical companies.
Halozyme Therapeutics Stock Price. Everything You Need To Know About The Halozyme Therapeutics Stock! performance
- Employees 393
- Company HQ San Diego
- Website https://www.halozyme.com/
- HALO Asset Type Common Stock
- HALO Market Capitalization 4.9B
- Earnings Per Share 2.1
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0.546
Halozyme Therapeutics is a leading biopharmaceutical company that specializes in developing novel therapies for the treatment of cancer and autoimmune diseases. With a strong focus on innovation and cutting-edge science, Halozyme Therapeutics has established itself as a pioneer in the field. If you are a retail investor from Malaysia, Thailand, Indonesia, or Vietnam and want to invest in Halozyme Therapeutics, here are a few steps to get started: 1. Research and Understand: Before investing in any stock, it is essential to thoroughly research and understand the company’s financials, products, and growth prospects. Halozyme Therapeutics has an impressive portfolio of products and partnerships that make it a promising investment opportunity. 2. Choose a Reliable Brokerage: To invest in Halozyme Therapeutics or any US stock, you will need a brokerage account that allows international investors. Look for a reputable brokerage that offers reliable services, access to US stock markets, and competitive fees. 3. Fund your Account: Once you have selected a brokerage, you will need to fund your account. Most brokerages offer various options, including wire transfer or online payment methods, to make the process seamless and efficient. 4. Execute the Trade: With your account funded, you can now place your order to invest in Halozyme Therapeutics. Determine the number of shares you want to purchase, set your desired price, and place the trade. Keep in mind that market conditions can affect the stock price, so it is essential to monitor the market closely. 5. Stay Informed: After investing in Halozyme Therapeutics, it is crucial to stay updated on the company’s news, developments, and financial reports. Regularly review your investments and adjust your strategy if needed. Investing in stocks, especially international ones, requires careful consideration and research. By following these steps and staying informed, retail investors from Malaysia, Thailand, Indonesia, and Vietnam can make informed decisions when investing in Halozyme Therapeutics.
